Bhagiradha Chemicals & Industries Limited (NSE: BHAGCHEM | BSE: 531719)
Source: Bhagiradha Chemicals & Industries Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Bhagiradha Chemicals & Industries Limited (BCIL) is an Indian research-driven agrochemical manufacturing enterprise specializing in high-science, technical-grade active ingredients, chemical intermediates, and speciality formulations. For over three decades, the company has established a commercial engine focused on synthesizing complex chemistries, executing deep backward integration, and supplying crop protection chemicals across domestic and international markets.
- Insecticides & Intermediates (17 Active Products): Represents BCIL’s largest chemical line. Core products include Chlorpyriphos (flagship organophosphate active), Fipronil (phenylpyrazole insecticide where BCIL commands a 27% domestic market share backed by deep backward integration), Thiamethoxam (neonicotinoid insecticide), Imidacloprid, and specialized intermediate compounds. Added 5 new insecticide actives/intermediates since FY 2019-20.
- Herbicides & Intermediates (13 Active Products): High-margin selective and systemic weed control solutions. Key technicals include Triclopyr (exported extensively to Australia and the US), Clodinafop Propargyl, and Cloquintocet Mexyl (herbicide safener). Added 2 new herbicide molecules since FY 2019-20.
- Fungicides & Intermediates (5 Active Products): Broad-spectrum disease management chemistries. Anchored by Azoxystrobin (strobilurin fungicide), where BCIL has achieved N-7 stage backward integration—the deepest level among Indian agrochemical peers—and is currently scaling process chemistries toward the N-9 stage. Commercialized Trifloxystrobin during FY 2025-26.
- Contract Manufacturing & CDMO Services: Custom Synthesis and Manufacturing of proprietary molecules and advanced intermediates for multinational innovator companies headquartered in Japan, the United States, Europe, and Israel. Supported by an 8-lab synthesis facility staffed by over 60 research chemists.
📋 Quick Facts / Company Snapshot: Bhagiradha Chemicals & Industries Limited (NSE: BHAGCHEM | BSE: 531719)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Bhagiradha Chemicals & Industries Limited |
| Corporate Identity Number (CIN) | L24219TG1993PLC015963 |
| International Securities Identification Number (ISIN) | INE414D01027 (Fully Paid-up Equity Shares of Face Value ₹1.00 each) |
| Stock Exchange Listing | BSE: 531719 | NSE: BHAGCHEM |
| Date of Incorporation / Founding Year | July 7, 1993 (Over 33 Years of Manufacturing Excellence) |
| Founders / Key Founding Figures | Late Sri Singavarapu Koteswara Rao (Distinguished Technocrat & Former IICT Hyderabad Scientist) |
| Registered Office & Corporate HQ | Unit No. 1011A, Level 1, Sky One (Wing A), Prestige SkyTech, Financial District, Nanakramguda, Gachibowli, Hyderabad, Telangana – 500032, India |
| Telephone & Official IR Email | +91-40-65440409 | info@bhagirad.com / cs@bhagirad.com |
| Chairman of the Board | Sri Kishor Shah (Independent Non-Executive Chairman) |
| Managing Director & CEO | Sri S. Chandra Sekhar (Managing Director) | Sri A. Arvind Kumar (Executive Director & Chief Executive Officer) |
| Chief Financial Officer & Company Secretary | Sri Ranjit Kumar Kilaru (CFO, w.e.f. March 1, 2026) | CS Sharanya. M (Company Secretary & Compliance Officer) |
| Promoter Group | Singavarapu Family & Greenpath Energy Private Limited (19.60% Total Equity Holding) |
| Industry / Sector Classification | Agrochemicals, Crop Protection Chemicals & Speciality Intermediates (NIC Code: 20211) |
| Total Workforce / Employee Count | 832 Total Workforce (224 Permanent Employees, 303 Permanent Workers, 305 Contractual Workers) |
| Manufacturing Complexes & R&D Footprint | 2 Manufacturing Facilities: Ongole (Andhra Pradesh – 3,250 MTPA) & Kadechur (Karnataka – 9,002 MTPA Target) | Government-Approved R&D Centre at Ongole |
| Credit Ratings & Rating Agency | India Ratings and Research (Ind-Ra): Term Loan (₹32.84 Crores) IND BBB+/Stable; Working Capital Limits (₹123.75 Crores) IND BBB+/Stable / IND A2+ |
| Statutory & Secretarial Auditors | Statutory Auditors: M/s R. Kankaria & Uttam Singhi, Chartered Accountants | Secretarial Auditors: M/s Puttaparthi Jagannatham & Co., Company Secretaries | Cost Auditors: M/s Sagar & Associates |
| Registrar & Share Transfer Agent (RTA) | M/s XL Softech Systems Limited, Plot No. 3, Sagar Society, Road No. 2, Banjara Hills, Hyderabad – 500034 (Email: ccare@xlsoftech.com) |
🏢 The Corporate Identity: Bhagiradha Chemicals Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Bhagiradha Chemicals & Industries Limited (BCIL) is an Indian research-driven agrochemical manufacturing enterprise specializing in high-science, technical-grade active ingredients, chemical intermediates, and speciality formulations. For over three decades, the company has established a commercial engine focused on synthesizing complex chemistries, executing deep backward integration, and supplying crop protection chemicals across domestic and international markets. Operating at the intersection of process chemistry and agricultural productivity, BCIL partners with global agrochemical innovators, B2C formulators, and generic chemical distributors.
The company operates a two-plant manufacturing framework anchored by its flagship complex at Ongole, Andhra Pradesh, and a newly commercialized greenfield complex at Kadechur, Karnataka (operated through its wholly-owned subsidiary, Bheema Fine Chemicals Private Limited). BCIL’s business model revolves around four core strategic pillars: high-science non-infringing process development, backward integration to basic raw material blocks (achieving up to N-7 level integration in key molecules), multi-process manufacturing flexibility, and long-term customer partnerships across semi-regulated and highly regulated global markets including the United States, European Union, Brazil, and Australia.
- Highest-Ever Consolidated Revenue: Recorded historic consolidated revenue from operations of ₹535.94 Crores in FY 2025-26, representing a growth of 21.67% YoY compared to ₹440.47 Crores in FY 2024-25.
- Consolidated EBITDA Expansion: Achieved an EBITDA of ₹59.50 Crores in FY 2025-26, registering a 28.72% YoY surge over ₹46.23 Crores in FY 2024-25.
- Expanding Global & Domestic Client Base: Active commercial customer relationships expanded to 149 active clients in FY 2025-26 (up 52% from 98 in FY 2020-21), spanning over 100 domestic agrochemical leaders and 25 multinational innovator corporations.
- Product Portfolio Diversification: Commercial portfolio expanded to 35 active molecules across insecticides, herbicides, fungicides, and intermediates, reducing revenue concentration of top-5 products from 95% in FY 2022-23 to 81% in FY 2025-26.
The Founders, Promoters & Their Legacy
Bhagiradha Chemicals was founded in 1993 by the late Sri Singavarapu Koteswara Rao, a distinguished technocrat and former scientist at the Indian Institute of Chemical Technology (IICT), Hyderabad. Built on scientific rigor and process innovation, the founder laid the groundwork for an R&D-led agrochemical company committed to enhancing agricultural crop yields and fostering food security through indigenous manufacturing of complex off-patent active ingredients.
The promoter legacy is carried forward by his son, Sri S. Chandra Sekhar, Managing Director, a chemical engineer who joined the enterprise in 2002 and spearheaded BCIL’s expansion into contract manufacturing, deep backward integration, and international regulatory registrations. The promoter group, comprising the Singavarapu family and corporate entity Greenpath Energy Private Limited, holds a 19.60% equity stake in the company as of March 31, 2026. The executive management team is led by Sri A. Arvind Kumar, Executive Director & CEO, an industry professional overseeing operational execution, technological upscaling, and capital expansion across both manufacturing assets.
The Journey: Corporate History & Key Milestones
From a single-product manufacturer established in 1993, Bhagiradha Chemicals has transitioned into a multi-site, multi-molecule agrochemical group over its 33-year operating history.
- 1993–1996: Incorporation of the company in Hyderabad and setup of the flagship manufacturing plant at Ongole, Andhra Pradesh, launching Chlorpyriphos as the flagship insecticide active. Successfully completed Initial Public Offer (IPO) and listed on the BSE in 1996.
- 1998–2005: Entered international regulated markets across the European Union, Australia, Peru, and Costa Rica. Sri S. Chandra Sekhar joined the management in 2002. Commissioned Production Block 2, established an in-house R&D facility, launched Triclopyr (herbicide) and Imidacloprid (insecticide), and commenced contract manufacturing for a major US-based multinational in 2005.
- 2008–2012: Commissioned Production Block 3 at Ongole, elevating total approved production capacity to 3,250 MTPA. Introduced global herbicide molecules Clodinafop Propargyl, Cloquintocet Mexyl, and Thiamethoxam. Achieved backward integration of Azoxystrobin (fungicide) to N-1 level in 2011 and N-5 level in 2012.
- 2014–2020: Commercialized three specialized contract manufacturing intermediates for US and Indian markets. Expanded international regulatory filings into Brazil and the EU. Achieved landmark N-7 level backward integration for Azoxystrobin in 2020—the deepest level of integration achieved by any Indian manufacturer. Incorporated wholly-owned subsidiary Bheema Fine Chemicals Private Limited in July 2020 for greenfield expansion.
- 2021–2026: Expanded into large-molecule chemistry with high-level backward integration for Fipronil in 2021, capturing a 27% domestic market share. Consolidated revenues crossed ₹500 Crores in FY 2023-24. Successfully commercialized Phase I of the ₹450 Crore Bheema Fine Chemicals plant at Kadechur, Karnataka on March 27, 2024. Added Trifloxystrobin and 2 other new molecules in FY 2025-26, expanding the portfolio to 35 commercial products.
The Corporate Umbrella & Group Structure
Bhagiradha Chemicals & Industries Limited functions as the ultimate holding and operating company of the group. The corporate organizational structure consists of the parent company and one wholly-owned operating subsidiary, forming an integrated manufacturing ecosystem across Andhra Pradesh and Karnataka.
Bheema Fine Chemicals Private Limited (WOS): Incorporated on July 22, 2020 (CIN: U24299TG2020PTC142050), Bheema Fine Chemicals is a 100% wholly-owned subsidiary established as BCIL’s strategic growth engine. Operating a 34-acre state-of-the-art complex in the KIADB Industrial Area, Kadechur, Yadgir District, Karnataka, Bheema Fine Chemicals represents a planned total investment program of over ₹850 Crores aimed at achieving an installed manufacturing capacity of 9,002 MTPA across two production blocks and five processing lines. Phase I was completed within the planned capital outlay of approximately ₹450.00 Crores (with ₹425.00 Crores capitalized as of FY26), generating initial operating revenues of ₹81.33 Crores and an EBITDA of ₹7.86 Crores in FY 2025-26 during its initial 35% capacity ramp-up phase.
⚙️ The Business Engine: Bhagiradha Chemicals Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
In accordance with Ind AS 108 (Operating Segments), the Group operates in a single primary business segment: Manufacture and Sale of Agrochemicals (Crop Protection Chemicals, Technicals, Intermediates, and Formulations). Operating performance is evaluated as an integrated chemical synthesis business.
| Business Segment / Activity | Segment Revenue (FY 2025-26) | % Share of Total Revenue | Segment Revenue (FY 2024-25) | % Share of Total Revenue | Latest YoY (%) |
|---|---|---|---|---|---|
| Agrochemical Manufacturing (Technicals, Intermediates & Formulations) | 531.28 | 99.13% | 439.00 | 99.67% | +21.02% |
| Traded Goods (Raw Material & Stock-in-Trade) | 4.58 | 0.85% | 1.31 | 0.30% | +249.62% |
| Other Operating Revenue (Export Incentives & Scrap Sales) | 0.08 | 0.02% | 0.16 | 0.03% | -50.00% |
| Total Revenue from Operations | 535.94 | 100.00% | 440.47 | 100.00% | +21.67% |
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
Bhagiradha Chemicals manufactures a portfolio of 35 commercialized active ingredients and intermediates categorized across three primary pesticide chemistry segments: Insecticides, Herbicides, and Fungicides.
- Insecticides & Intermediates (17 Active Products): Represents BCIL’s largest chemical line. Core products include Chlorpyriphos (flagship organophosphate active), Fipronil (phenylpyrazole insecticide where BCIL commands a 27% domestic market share backed by deep backward integration), Thiamethoxam (neonicotinoid insecticide), Imidacloprid, and specialized intermediate compounds. Added 5 new insecticide actives/intermediates since FY 2019-20.
- Herbicides & Intermediates (13 Active Products): High-margin selective and systemic weed control solutions. Key technicals include Triclopyr (exported extensively to Australia and the US), Clodinafop Propargyl, and Cloquintocet Mexyl (herbicide safener). Added 2 new herbicide molecules since FY 2019-20.
- Fungicides & Intermediates (5 Active Products): Broad-spectrum disease management chemistries. Anchored by Azoxystrobin (strobilurin fungicide), where BCIL has achieved N-7 stage backward integration—the deepest level among Indian agrochemical peers—and is currently scaling process chemistries toward the N-9 stage. Commercialized Trifloxystrobin during FY 2025-26.
- Contract Manufacturing & CDMO Services: Custom Synthesis and Manufacturing of proprietary molecules and advanced intermediates for multinational innovator companies headquartered in Japan, the United States, Europe, and Israel. Supported by an 8-lab synthesis facility staffed by over 60 research chemists.
Operational KPIs & Capacity Utilization: The flagship Ongole plant operated at 94% capacity utilization during FY 2025-26 on its approved 3,250 MTPA capacity. The newly commissioned Bheema Fine Chemicals plant at Kadechur (9,002 MTPA total installed capacity target) operated at approximately 35% capacity utilization as of March 31, 2026, consistent with the standard 12-to-24 month stabilization cycle typical of large-scale multi-process chemical complexes. Management projects steady volume ramp-ups driving revenue growth through FY 2026-27 and FY 2027-28.
Ind AS 108 Customer Concentration Disclosure: In accordance with Ind AS 108, the Group disclosed that during FY 2025-26, two external customers individually accounted for 10% or more of total revenue from operations, contributing an aggregate of ₹114.24 Crores (21.32% of total revenue). In FY 2024-25, no single external customer contributed 10% or more to total revenues. Revenue concentration among the top 5 products declined from 95% in FY23 to 85% in FY25 and 81% in FY26, illustrating structural portfolio diversification.
Raw Material Sourcing & Import Dependence: Total raw materials consumed in FY 2025-26 stood at ₹335.81 Crores. Total foreign exchange outgo on imported raw materials and capital goods was ₹90.75 Crores, representing an import reliance of approximately 27% on key imported intermediates (primarily sourced from China), while 73% of raw material inputs were procured domestically.
The Names You Know: Key Brands & Flagship Portfolio
| Product / Chemical Active | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Azoxystrobin Technical | Fungicide & Intermediates | Broad-spectrum strobilurin fungicide. Process integrated up to N-7 stage (deepest in India), targeting domestic and regulated export markets (USA, EU, Brazil). |
| Fipronil Technical | Insecticide & Intermediates | Broad-spectrum phenylpyrazole insecticide. Highly backward-integrated, supporting a 27% market share in the Indian domestic B2B market. |
| Chlorpyriphos Technical | Insecticide & Intermediates | BCIL’s legacy flagship organophosphate active ingredient, supplied to major formulators across domestic and international agricultural regions. |
| Triclopyr Technical | Herbicide & Intermediates | Selective pyridine herbicide utilized for woody plant and broadleaf weed control, holding registrations and customer bases in Australia and North America. |
| Thiamethoxam Technical | Insecticide & Intermediates | Second-generation neonicotinoid active offering systemic soil and foliar control against sucking pests in field and horticultural crops. |
| Trifloxystrobin Technical | Fungicide & Intermediates | New-generation strobilurin fungicide commercialized in FY 2025-26, expanding BCIL’s high-margin fruit and vegetable disease control portfolio. |
| Clodinafop Propargyl & Cloquintocet Mexyl | Herbicide & Safener | Graminicide technical and paired safener chemistry deployed extensively for post-emergence grass weed management in cereal crops. |
Mapping the Domestic & Global Reach (India vs. Exports)
Bhagiradha Chemicals supplies technicals and intermediates across 18 Indian States/Union Territories and exports to key agricultural markets across 5 international continents.
| Geographic Market | FY 2025-26 Revenue | % Share (FY26) | FY 2024-25 Revenue | % Share (FY25) | Latest YoY (%) |
|---|---|---|---|---|---|
| India (Domestic Sales) | 523.43 | 97.50% | 426.42 | 96.85% | +22.75% |
| Asia (International) | 10.01 | 1.87% | 6.75 | 1.53% | +48.30% |
| Europe | 2.42 | 0.45% | 2.83 | 0.64% | -14.49% |
| South America (Brazil & LatAm) | 0.00 | 0.00% | 2.38 | 0.54% | -100.00% |
| Australia & Others | 0.00 | 0.00% | 1.93 | 0.44% | -100.00% |
| Total Revenues | ₹535.86 Cr* | 100.00% | ₹440.31 Cr* | 100.00% | +21.70% |
*Note: Geographic segment breakdown reflects customer location disclosures under Note 48 of the Consolidated Financial Statements. Total direct foreign export earnings in FY 2025-26 stood at ₹12.81 Crores (2.50% of total revenue).
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
BCIL’s industrial operations comprise two modern chemical manufacturing complexes and dedicated research infrastructure:
- Ongole Manufacturing Complex (Andhra Pradesh): Flagship manufacturing site spread across 29 hectares (approx. 72 acres) in Cheruvukommupalem Village, Ongole Mandal, Prakasam District, Andhra Pradesh (approx. 95 miles from Amaravati). Features 3 production blocks housing 4 multi-purpose synthesis lines with an aggregate built-up area of 76,000 sq. ft. Total approved production capacity: 3,250 MTPA. Equipped with a Zero Liquid Discharge (ZLD) effluent treatment facility, multiple-effect evaporators (MEE), agitated thin-film dryers (ATFD), electro-oxidation COD treatment systems, and a 4 MW behind-the-meter solar power plant commissioned in April 2025.
- Kadechur Manufacturing Complex (Bheema Fine Chemicals, Karnataka): Greenfield manufacturing complex spread across 34 acres in the KIADB Industrial Area, Kadechur, Yadgir District, Karnataka. Phase I completed at a capital outlay of ~₹450 Crores, featuring 2 processing blocks, 5 proposed process lines, Distributed Control Systems (DCS) automation, advanced ZLD plant, assured water infrastructure, and 8 synthesis labs staffed by over 60 chemists. Total planned expansion program (₹850+ Crores) will raise group capacity by 9,002 MTPA. Commercial production commenced on March 27, 2024.
- Government-Approved R&D Centre (Ongole): In-house research facility recognized by the Department of Scientific and Industrial Research (DSIR), Ministry of Science & Technology, Government of India. Staffed by qualified process engineers and organic chemists focused on non-infringing process synthesis, pilot plant scale-up, safety hazard evaluation, and backward integration chemistry.
- Registered & Corporate Office (Hyderabad): Owned corporate office space acquired in FY 2024-25, located at Unit No. 1011A, Level 1, Sky One (Wing A), Prestige SkyTech, Financial District, Nanakramguda, Hyderabad, Telangana – 500032.
📊 The Financial Health: Bhagiradha Chemicals Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
| Financial Metric | FY 2025-26 (Cons) | FY 2024-25 (Cons) | FY 2023-24 (St) | FY 2022-23 (St) | FY 2021-22 (St) | Latest YoY (%) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 535.94 | 440.47 | 407.00 | 502.00 | 436.00 | +21.67% |
| EBITDA | 59.50 | 46.23 | 48.00 | 80.00 | 69.00 | +28.70% |
| EBITDA Margin (%) | 11.10% | 10.50% | 11.59% | 15.81% | 15.85% | – |
| Profit Before Tax (PBT) | 21.11 | 25.25 | ₹27.00 Cr* | ₹61.00 Cr* | ₹48.00 Cr* | -16.40% |
| Profit After Tax (PAT) | 18.17 | 13.86 | 20.00 | 46.00 | 36.00 | +31.10% |
| Net Profit Margin (%) | 18.17 | 3.15% | 4.93% | 9.21% | 8.22% | – |
| Net Worth / Total Equity | 698.32 | 682.22 | 417.00 | 315.00 | 190.00 | +2.36% |
| Net Fixed Assets (PPE) | 573.94 | 238.16 | 176.00 | 164.00 | 149.00 | +140.99% |
| Basic Earnings Per Share (₹) | 1.40 | 1.14 | 1.95 | 4.56 | 4.32 | +22.81% |
*Note: Figures for FY22 to FY24 reflect Standalone key performance indicators disclosed on Page 15 of the Annual Report (adjusted for stock split to face value ₹1.00 per share). FY25 and FY26 represent audited Consolidated Ind AS numbers.
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
| Consolidated Statement of Profit & Loss Line Item | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 535.94 | 440.47 | +21.67% |
| Other Income | 2.36 | 9.28 | -74.57% |
| TOTAL INCOME | 538.31 | 449.75 | +19.69% |
| Cost of Materials Consumed | 339.96 | 279.01 | +21.85% |
| Purchase of Stock-in-Trade | 2.28 | 0.00 | N/M |
| Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade | (₹7.05 Cr) | (₹0.88 Cr) | +701.14% |
| Employee Benefits Expense | 49.46 | 40.68 | +21.58% |
| Finance Costs | 17.46 | 7.11 | +145.57% |
| Depreciation and Amortization Expense | 20.93 | 13.86 | +51.01% |
| Other Expenses (Manufacturing, Power, Freight, CSR & Admin) | 94.15 | 84.71 | +11.14% |
| TOTAL EXPENSES | 517.20 | 424.50 | +21.84% |
| Profit Before Tax (PBT) | 21.11 | 25.25 | -16.40% |
| Total Tax Expense (Current Tax + Deferred Tax + MAT) | 2.93 | 11.39 | -74.28% |
| PROFIT AFTER TAX (PAT) FOR THE YEAR | 18.17 | 13.86 | +31.10% |
| Other Comprehensive Income / (Loss) (Net of Tax) | (₹0.13 Cr) | 0.10 | N/M |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR | 18.05 | 13.96 | +29.30% |
P&L Financial Insights & Operational Drivers: Consolidated revenue grew by 21.67% YoY in FY 2025-26, driven by higher sales volumes, customer base expansion (19 new clients added), and initial commercial revenue contributions of ₹81.33 Crores from Bheema Fine Chemicals. Raw material consumption expanded from ₹279.01 Crores to ₹339.96 Crores, mirroring higher production throughput. Employee benefit costs rose by 21.58% to ₹49.46 Crores due to workforce additions at the new Kadechur facility. Depreciation increased by 51.01% to ₹20.93 Crores, and finance costs surged by 145.57% to ₹17.46 Crores following the capitalization of Phase I assets at Bheema Fine Chemicals. Net Profit after tax registered an growth of 31.10% YoY, reaching ₹18.17 Crores compared to ₹13.86 Crores in FY 2024-25, benefited by a lower effective tax rate due to deferred tax credits.
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
| Consolidated Balance Sheet Line Item | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| ASSETS | |||
| Non-Current Assets | |||
| Property, Plant and Equipment | 573.94 | 238.16 | +140.99% |
| Right of Use Assets | 4.52 | 5.01 | -9.78% |
| Capital Work-in-Progress (CWIP) | 94.22 | 287.81 | -67.26% |
| Other Intangible Assets & Assets under Development | 2.85 | 3.07 | -7.17% |
| Other Non-Current Financial Assets | 6.63 | 5.92 | +11.99% |
| Other Non-Current Assets (Capital Advances & Prepaids) | 1.53 | 18.31 | -91.64% |
| Total Non-Current Assets | 683.70 | 558.28 | +22.47% |
| Current Assets | |||
| Inventories | 145.75 | 129.71 | +12.37% |
| Trade Receivables | 204.68 | 173.86 | +17.73% |
| Cash and Cash Equivalents | 16.35 | 28.23 | -42.08% |
| Bank Balances other than Cash & Cash Equivalents | 2.57 | 1.56 | +64.74% |
| Other Current Financial Assets & Tax Assets | 1.51 | 0.43 | +251.16% |
| Other Current Assets (Advance to Suppliers & Balances with Govt) | 65.62 | 41.09 | +59.70% |
| Total Current Assets | 436.49 | 374.88 | +16.43% |
| TOTAL ASSETS | 1,120.19 | 933.15 | +20.04% |
| EQUITY AND LIABILITIES | |||
| Equity Share Capital | 12.97 | 12.97 | 0.00% |
| Other Equity (Securities Premium, General Reserve & Retained Earnings) | 685.36 | 669.26 | +2.41% |
| TOTAL EQUITY / NET WORTH | 698.32 | 682.22 | +2.36% |
| Non-Current Liabilities | |||
| Non-Current Borrowings (Term Loans & Sales Tax Deferment) | 153.14 | 30.05 | +409.62% |
| Non-Current Lease Liabilities | 2.35 | 3.23 | -27.24% |
| Other Non-Current Liabilities, Provisions & Deferred Tax (Net) | 20.84 | 22.40 | -6.96% |
| Total Non-Current Liabilities | 176.33 | 55.68 | +216.68% |
| Current Liabilities | |||
| Current Borrowings (Working Capital Loans & Current Portion of Term Debt) | 77.92 | 54.40 | +43.24% |
| Trade Payables (MSME & Other Suppliers) | 138.09 | 93.18 | +48.20% |
| Other Current Financial Liabilities, Lease Liabilities, Provisions & Tax | 29.53 | 47.68 | -38.07% |
| Total Current Liabilities | 245.54 | 195.26 | +25.75% |
| Total Liabilities (Excluding Equity) | 421.87 | 250.93 | +68.12% |
| TOTAL EQUITY AND LIABILITIES | 1,120.19 | 933.15 | +20.04% |
Balance Sheet Structure & Asset Capitalization: The group’s Balance Sheet expanded significantly during FY 2025-26, with Total Assets growing from ₹933.15 Crores to ₹1,120.19 Crores (up 20.04%). This growth reflects the capitalization of Phase I of the Bheema Fine Chemicals project, which transferred ₹1.94 Crores from Capital Work-in-Progress (CWIP reduced from ₹287.81 Crores to ₹94.22 Crores) into active Property, Plant & Equipment (PPE expanded from ₹238.16 Crores to ₹573.94 Crores). Non-current borrowings increased from ₹30.05 Crores to ₹153.14 Crores as term loans drawn for Bheema Fine Chemicals Phase I were capitalized. Total Debt (Long-Term + Short-Term Borrowings) stood at ₹231.06 Crores, maintaining a conservative Debt-to-Equity ratio of 0.33x against a consolidated Net Worth of ₹698.32 Crores.
Working Capital Cycle & Schedule III Statutory Ratio Explanations
| Financial / Statutory Ratio | FY 2025-26 | FY 2024-25 | YoY Change (%) | Management Explanation / Operational Rationale |
|---|---|---|---|---|
| Debtors Turnover Ratio (times) | 2.79 | 3.12 | -10.58% | Marginal increase in receivable collection period in line with agrochemical industry seasonal terms. |
| Inventory Turnover Ratio (times) | 14.94 | 8.60 | +73.72% | Significant improvement driven by overall growth in business volumes and faster inventory monetization. |
| Interest Coverage Ratio (times) | 3.65 | 7.03 | -48.07% | Variation due to higher working capital utilization and term loan interest costs following Bheema capitalization. |
| Current Ratio (times) | 1.80 | 4.10 | -56.14% | Deployment of short-term funds into revenue-generating assets and commercialization of Bheema Phase I plant. |
| Debt-Equity Ratio (times) | 0.13 | 0.11 | +17.29% | Marginal increase due to higher working capital borrowing drawdowns supporting expanded plant operations. |
| Operating Profit Margin (%) | 8.19% | 7.33% | +11.73% | Higher business volumes and operational absorption enabled expansion in operating profit margins. |
| Net Profit Margin (%) | 18.17 | 6.00% | -16.95% | Reduction driven primarily by lower non-operational income compared to the previous financial year. |
| Return on Net Worth (RONW %) | 3.63% | 3.92% | -7.41% | Marginal fall attributable to lower non-operating income despite core operational profit expansion. |
Cash Flow: Tracking the Money Movement
| Consolidated Statement of Cash Flows Summary | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| Net Cash Flow from / (used in) Operating Activities | 12.01 | (₹52.80 Cr) | N/M |
| Net Cash Flow used in Investing Activities | (₹160.17 Cr) | (₹200.56 Cr) | -20.14% |
| Included CapEx / Purchase of PPE & CWIP (Net) | 160.14 | 252.28 | -36.52% |
| Net Cash Flow from Financing Activities | 136.28 | 271.66 | -49.83% |
| Included Dividends Paid on Equity Shares | (₹1.95 Cr) | (₹1.24 Cr) | +57.26% |
| Net Increase / (Decrease) in Cash & Cash Equivalents | (₹11.88 Cr) | 18.30 | N/M |
| Cash & Cash Equivalents at Beginning of Year | 28.23 | 9.92 | +184.58% |
| CASH & CASH EQUIVALENTS AT END OF YEAR | 16.35 | 28.23 | -42.08% |
Cash Flow Dynamics: Operating cash flow staged a sharp recovery in FY 2025-26, turning positive to ₹12.01 Crores (compared to negative ₹52.80 Crores in FY 2024-25) as operating profits expanded and working capital stabilized. Investing cash outflows of ₹160.17 Crores reflected ongoing capital expenditure at Kadechur and the 4 MW solar plant construction. Financing cash inflows of ₹136.28 Crores were driven by net long-term debt drawdowns of ₹123.13 Crores and short-term debt of ₹23.52 Crores, offset by ₹7.18 Crores in interest payments and ₹1.95 Crores in dividend payouts.
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
BCIL’s growth strategy centers on capital investments in manufacturing assets, renewable energy, and R&D capabilities.
- CapEx & CWIP Deployment: Capitalized ₹366.61 Crores of assets into Property, Plant & Equipment during FY 2025-26, including Phase I of Bheema Fine Chemicals (production blocks, DCS automation, ZLD plant) and the 4 MW solar plant at Ongole. Capital Work-in-Progress (CWIP) as of March 31, 2026, stood at ₹94.22 Crores, representing ongoing infrastructure work for Phase II expansion.
- 4 MW Behind-The-Meter Solar Power Plant: Invested ₹16.00 Crores to construct a 4,000.44 KWp behind-the-meter solar power unit at the Ongole factory, commissioned in April 2025. Generates approximately 5.20 lakh power units per month, supplying 20% of the plant’s annual electricity requirement from clean renewable energy and reducing power costs.
- R&D Intensity: Total R&D expenditure in FY 2025-26 stood at ₹3.50 Crores (₹0.37 Crores capital expenditure and ₹3.13 Crores recurring revenue expenditure), representing 0.66% of standalone turnover. R&D efforts delivered 3 new commercialized molecules and scaled Azoxystrobin backward integration toward the N-9 stage.
- Net Foreign Exchange Earnings: Total foreign exchange earned through direct exports stood at ₹12.81 Crores. Total foreign exchange outgo was ₹90.75 Crores (primarily for imported raw material inputs), resulting in a net foreign exchange utilization of ₹77.94 Crores.
👥 Power & Control: Bhagiradha Chemicals Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
The Board of Directors of Bhagiradha Chemicals consists of 7 members, comprising 2 Executive Directors, 3 Non-Executive Independent Directors (including an Independent Chairman and a Woman Director), and 2 Non-Executive Non-Independent Directors.
| Name of Director / KMP | Designation / Role | DIN / Membership | Category |
|---|---|---|---|
| Sri Kishor Shah | Chairman & Independent Director | DIN: 00193288 | Non-Executive Independent Director |
| Sri S. Chandra Sekhar | Managing Director | DIN: 00159543 | Executive Director (Promoter) |
| Sri A. Arvind Kumar | Executive Director & CEO | DIN: 03097192 | Executive Director & Key Managerial Personnel |
| Sri G.S.V. Krishna Rao | Independent Director | DIN: 08199210 | Non-Executive Independent Director |
| Dr. G. Aruna | Independent Woman Director | DIN: 08978947 | Non-Executive Independent Director |
| Sri Suresh Kumar Somani | Non-Executive Director | DIN: 00031096 | Non-Executive Non-Independent Director |
| Smt. Lalitha Sree Singavarapu | Non-Executive Director | DIN: 06957985 | Non-Executive Non-Independent Director (Promoter) |
| Sri Ranjit Kumar Kilaru | Chief Financial Officer (CFO) | KMP (w.e.f. Mar 1, 2026) | Key Managerial Personnel |
| CS Sharanya. M | Company Secretary & Compliance Officer | FCS-13842 | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
As of March 31, 2026, the company’s paid-up share capital stood at ₹12.97 Crores divided into 12,96,69,080 equity shares of face value ₹1.00 each.
| Shareholder Category | Number of Shares Held | % of Total Issued Shares |
|---|---|---|
| Promoter & Promoter Group | 2,54,10,000 | 19.60% |
| Alternative Investment Funds (AIFs) | 39,16,337 | 3.02% |
| Foreign Portfolio Investors (FPIs) | 1,85,539 | 0.14% |
| Bodies Corporate (Includes Ratnabali Investment Pvt Ltd) | 5,44,61,088 | 42.00% |
| Public Individuals (Nominal Capital > ₹0.0200 Crores) | 2,84,16,123 | 21.91% |
| Public Individuals (Nominal Capital ≤ ₹0.0200 Crores) | 1,32,29,226 | 10.20% |
| Non-Resident Indians (NRIs) | 22,52,315 | 1.74% |
| HUF, Trusts, IEPF & Directors/Relatives | 17,98,452 | 1.39% |
| Total Equity Shares | 12,96,69,080 | 100.00% |
Promoter & Key Institutional Stakes: Managing Director Sri S. Chandra Sekhar holds 1,67,27,740 shares (12.90%), Greenpath Energy Private Limited holds 47,68,230 shares (3.68%), and Smt. Eadara Jayalaxmi holds 24,73,210 shares (1.91%). Among major non-promoter corporate investors, Ratnabali Investment Private Limited (associated with Director Sri Suresh Kumar Somani) holds 1,82,48,320 equity shares, representing a 14.07% equity stake. During FY 2025-26, three promoter group members (T. Kalyan Chakravarthi, Potini Vijaya Lakshmi, and Ramalakshmi Tulasi Padmavathy Kolli holding 0.15% combined) were reclassified into the Public Category following approval from BSE and NSE on August 7, 2025.
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
Bhagiradha Chemicals has one wholly-owned subsidiary and no associate or joint venture companies as of March 31, 2026.
| Entity Name | Relationship & Country | % Holding | FY26 Revenue | FY26 PBT | FY26 PAT |
|---|---|---|---|---|---|
| Bheema Fine Chemicals Private Limited | Wholly-Owned Subsidiary (India) | 100.00% | ₹81.33 Cr | (₹6.04 Cr) |
Subsidiary Capital Restructuring: On May 14, 2025, Bheema Fine Chemicals Private Limited allotted 4,08,36,237 equity shares of face value ₹10 each at an issue price of ₹90 per share (including a premium of ₹80 per share) to BCIL on a private placement basis. This preferential allotment converted ₹367.53 Crores of outstanding inter-company loans and accrued interest extended by BCIL into permanent equity capital, strengthening the subsidiary’s balance sheet.
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
Credit Ratings: On March 9, 2026, credit rating agency India Ratings and Research (Ind-Ra) affirmed BCIL’s long-term issuer rating at IND BBB+/Stable and short-term rating at IND A2+, revising the rating outlook from Rating Watch with Developing Implications to Stable. The rating applies across ₹32.84 Crores of term loans, ₹84.00 Crores of fund-based working capital limits, ₹39.75 Crores of non-fund based limits, and ₹16.41 Crores of proposed facilities.
Banking Consortium: Credit facilities are syndicated through a consortium led by State Bank of India (Saifabad Branch, Hyderabad), Axis Bank Limited (Begumpet Main Branch), RBL Bank Limited (Madhapur Branch), and ICICI Bank Limited (Jubilee Hills Branch).
Off-Balance Sheet Contingent Liabilities & Capital Commitments: Total contingent liabilities as of March 31, 2026, stood at ₹154.21 Crores, primarily comprising corporate guarantees of ₹140.82 Crores extended by BCIL to lenders of Bheema Fine Chemicals, bank guarantees of ₹0.38 Crores, letters of credit of ₹10.71 Crores, indirect tax disputes of ₹1.15 Crores (GST, Entry Tax, and Customs Duty), income tax appeals of ₹0.72 Crores (A.Y. 2010-11), and electricity fuel adjustment charges under appeal of ₹0.45 Crores. Estimated capital commitments remaining to be executed on capital account stood at ₹1.90 Crores.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
- Deep Backward Integration (N-7/N-9 Capability): BCIL’s synthesis of Azoxystrobin down to the N-7 stage (and active development toward N-9) and Fipronil integration represents one of the deepest backward-integrated process frameworks among Indian generic technical manufacturers. This insulates gross margins against imported chemical cost spikes, secures raw material access, and creates significant entry barriers.
- Multi-Site Manufacturing Scale (12,252 MTPA Total Target): Operating 3,250 MTPA at Ongole alongside 9,002 MTPA at Kadechur provides dual-plant operational flexibility, multi-product campaign capability, and de-risked supply chains for global innovator clients.
- In-House Process R&D & Non-Infringing Chemistry: DSIR-recognized R&D facility with a track record of developing cost-effective, non-infringing synthesis routes for off-patent active ingredients, driving commercial launch of 35 active molecules.
- Sticky Global Customer Relationships: Customer relationships average over 10 years across a commercial base of 149 clients, encompassing top domestic B2C formulators and 25 global multinationals with registrations across the US, EU, Brazil, and Australia.
What Could Go Wrong? Key Challenges & Business Risks
- Raw Material Volatility & China Import Reliance: Approx 27% of raw material inputs depend on Chinese chemical intermediate imports. Geopolitical tensions, freight spikes, or export restrictions from China could compress gross margins.
- Capacity Ramp-up & Operating Leverage Risk at Kadechur: Bheema Fine Chemicals operated at ~35% utilization in FY26. Delayed customer registrations, slow product commercialization, or unabsorbed fixed costs (depreciation of ₹20.93 Cr and interest of ₹17.46 Cr) could weigh on consolidated net margins during the stabilization phase.
- Monsoon Dependence & Agro-Climatic Sensitivity: Over 97% of revenues stem from the Indian domestic agricultural market, leaving demand vulnerable to delayed monsoon rains, pest pressure fluctuations, or shifting cropping patterns.
- Environmental & Regulatory Compliance Risks: Operating zero liquid discharge (ZLD) chemical plants entails strict regulatory oversight from Pollution Control Boards. Non-compliance could lead to operational interruptions or capital expenditures.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Bhagiradha Chemicals has outlined a strategic growth framework targeting a 3.5x expansion in consolidated revenue over the next 4 to 5 years, transitioning from a capital-intensive investment cycle into asset utilization and cash generation.
- Ramp-Up of Bheema Phase I Facility: Accelerating capacity utilization at the ₹450 Crore Kadechur plant from 35% toward optimal levels over FY 2026-27 and FY 2027-28, introducing 6 to 10 new agrochemical active ingredients.
- Execution of Bheema Phase II Expansion: Initiating Phase II capital expansion at Kadechur involving an estimated investment of ~₹400.00 Crores, targeted for completion in Q2 FY 2027-28 to bring total group capacity to 12,252 MTPA.
- Expansion of CDMO / Custom Manufacturing Business: Scaling collaborative R&D and custom synthesis relationships with innovator agrochemical firms across Japan, Europe, Israel, and the United States.
- Deepening Backward Integration: Extending Azoxystrobin process chemistry to the N-9 level and advancing integration across flagship insecticide and herbicide lines to expand gross profit margins.
The Verdict: Strategic Outlook & Conclusion
Bhagiradha Chemicals & Industries Limited has transformed its operational profile from a single-plant enterprise into a multi-site chemical synthesis group. Having completed Phase I of its capital expenditure program at Bheema Fine Chemicals and achieving record consolidated revenues of ₹535.94 Crores in FY 2025-26, BCIL is positioned to leverage its expanded 12,252 MTPA asset base. Backed by a conservative Debt-to-Equity ratio of 0.33x, deep backward integration, 35 commercial molecules, and an active global client base of 149 customers, BCIL offers a scaled platform for long-term value creation in the crop protection and speciality chemical industry.
Frequently Asked Questions (FAQs) About Bhagiradha Chemicals
Q1: What does Bhagiradha Chemicals manufacture and what are its main products?
Bhagiradha Chemicals & Industries Limited manufactures technical-grade crop protection chemicals, chemical intermediates, and formulations. Its portfolio consists of 35 commercialized active molecules across insecticides (Chlorpyriphos, Fipronil, Thiamethoxam), herbicides (Triclopyr, Clodinafop Propargyl), and fungicides (Azoxystrobin, Trifloxystrobin).
Q2: What were Bhagiradha Chemicals’ revenue and net profit figures in FY 2025-26?
In FY 2025-26, Bhagiradha Chemicals achieved its highest-ever consolidated revenue from operations of ₹535.94 Crores (up 21.67% YoY from ₹440.47 Crores) and a consolidated Profit After Tax (PAT) of ₹18.17 Crores (up 31.10% YoY from ₹13.86 Crores). Consolidated EBITDA stood at ₹59.50 Crores.
Q3: Who founded Bhagiradha Chemicals and who currently manages the company?
Bhagiradha Chemicals was founded in 1993 by the late Sri Singavarapu Koteswara Rao, a technocrat and former scientist at IICT Hyderabad. The company is currently managed by his son, Sri S. Chandra Sekhar (Managing Director), Sri A. Arvind Kumar (Executive Director & CEO), and guided by an independent board chaired by Sri Kishor Shah.
Q4: Where are Bhagiradha Chemicals’ manufacturing plants located and what is its production capacity?
BCIL operates two manufacturing complexes: a 29-hectare flagship plant in Ongole, Andhra Pradesh (approved capacity: 3,250 MTPA operating at 94% utilization), and a greenfield 34-acre plant in Kadechur, Karnataka operated via subsidiary Bheema Fine Chemicals (total planned capacity: 9,002 MTPA). Combined group capacity will reach 12,252 MTPA upon completion of Phase II expansion.
Q5: What is Bhagiradha Chemicals’ debt profile, credit rating, and net worth?
As of March 31, 2026, BCIL reported a consolidated Net Worth of ₹698.32 Crores and total borrowings of ₹231.06 Crores (₹153.14 Crores long-term debt and ₹77.92 Crores short-term debt), resulting in a debt-to-equity ratio of 0.33x. India Ratings and Research (Ind-Ra) rates BCIL’s bank facilities at IND BBB+/Stable / IND A2+.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.bhagirad.com/